Key Takeaways
What is nerandomilast?
Nerandomilast is an oral preferential PDE4B inhibitor with immunomodulatory, vascular, and antifibrotic effects, evaluated in the phase 3 FIBRONEER-ILD trial in progressive pulmonary fibrosis.
Did time since ILD diagnosis affect nerandomilast response?
No. Among 325 patients with autoimmune ILD, interaction tests showed no heterogeneity in the effect on FVC at week 52 or on time to exacerbation, respiratory hospitalization, or death.
Which autoimmune diseases were most represented?
Rheumatoid arthritis accounted for 36.3% and systemic sclerosis for 23.1% of patients with autoimmune ILD in the analysis.






